GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » Shiller PE Ratio

Actinium Pharmaceuticals (Actinium Pharmaceuticals) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Actinium Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Actinium Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Shiller PE Ratio Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actinium Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actinium Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Actinium Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Shiller PE Ratio falls into.



Actinium Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Actinium Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Actinium Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.31/131.7762*131.7762
=-0.310

Current CPI (Mar. 2024) = 131.7762.

Actinium Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 3.000 100.560 3.931
201409 -6.300 100.428 -8.267
201412 -5.100 99.070 -6.784
201503 -2.700 99.621 -3.571
201506 -6.000 100.684 -7.853
201509 -3.000 100.392 -3.938
201512 -4.800 99.792 -6.338
201603 -3.000 100.470 -3.935
201606 -4.200 101.688 -5.443
201609 -4.200 101.861 -5.433
201612 -3.600 101.863 -4.657
201703 -4.200 102.862 -5.381
201706 -3.600 103.349 -4.590
201709 -2.700 104.136 -3.417
201712 -1.800 104.011 -2.280
201803 -2.100 105.290 -2.628
201806 -1.200 106.317 -1.487
201809 -1.800 106.507 -2.227
201812 -1.500 105.998 -1.865
201903 -1.500 107.251 -1.843
201906 -0.999 108.070 -1.218
201909 -1.210 108.329 -1.472
201912 -0.800 108.420 -0.972
202003 -0.980 108.902 -1.186
202006 -0.410 108.767 -0.497
202009 -0.360 109.815 -0.432
202012 -0.370 109.897 -0.444
202103 -0.290 111.754 -0.342
202106 -0.250 114.631 -0.287
202109 -0.300 115.734 -0.342
202112 -0.360 117.630 -0.403
202203 -0.230 121.301 -0.250
202206 -0.330 125.017 -0.348
202209 -0.380 125.227 -0.400
202212 -0.430 125.222 -0.453
202303 -0.430 127.348 -0.445
202306 -0.580 128.729 -0.594
202309 -0.490 129.860 -0.497
202312 -0.330 129.419 -0.336
202403 -0.310 131.776 -0.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Actinium Pharmaceuticals  (AMEX:ATNM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Actinium Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals (Actinium Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
275 Madison Avenue, 7th Floor, New York, NY, USA, 10016
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Executives
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin officer: VP, Finance and Corporate Dev. 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig officer: Chief Scientific Officer 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell director 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty director 643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur officer: Chief Commercial Officer 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray officer: Executive Vice President 14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center 10 percent owner 1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa director 138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave director, officer: President and CEO 4 WATER STREET, EDISON NJ 08820
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc 10 percent owner C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd. 10 percent owner C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000

Actinium Pharmaceuticals (Actinium Pharmaceuticals) Headlines

From GuruFocus